Tony Shen
Adult Reconstructive Orthopaedic Surgery · New York, NYNPI 1104367374
Payments from drug & device makers
What this record shows
This record is dominated by education: $12,542 of the $17,595 with a category attached, or 71.3%. Smith+Nephew accounts for 69.1% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $8,972 and has fallen 98.4% since, to $140 in 2025.
Across 39 payments — averaging $451.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$12K
- Zimmer Biomet$4K
- Stryker$680
- UOC USA Inc$321
- Johnson & Johnson$156
- Orthalign Inc$141
What the payments were for
- Consulting fees$1,75010%
- Travel & lodging$1,4318%
- Food & beverage$1,87211%
- Education$12,54271%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 3 | $12,150 |
| Zimmer Biomet | 19 | $4,147 |
| Stryker | 12 | $680 |
| UOC USA Inc | 2 | $321 |
| Johnson & Johnson | 2 | $156 |
| Orthalign Inc | 1 | $141 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ROSA$1,119
- Persona$773
- MAKO$430
- Avenir$185
- Conformity and Momentum Cup$181
- REAL INTELLIGENCE$150
- ORTHALIGN PLUS$141
- UTS, Conformity, U-MII, U2 Revision Stem, PSA, USTAR, U2 Knee$140
- Velys$135
- TRIATHLON$132
How this compares
$17,595 in reported general payments places this provider in the 55th percentile of 85 adult reconstructive orthopaedic surgery providers in New York.
See all adult reconstructive orthopaedic surgery providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 22 | $116 |
| Meloxicam | 37 | $74 |
| Amoxicillin | 27 | $23 |
Paid to pharmacies, not to this prescriber.
Other adult reconstructive orthopaedic surgery in New York
- Seth JerabekNew York$7.1M
- Jose RodriguezNew York$3.4M
- Friedrich BoettnerNew York$2.9M
- Jonathan VigdorchikNew York$2.3M
- William LongNew York$1.5M
- Peter SculcoNew York$1.5M
- Roshan ShahNew York$1.3M
- Herbert CooperNew York$1.3M
- Matthew AustinNew York$986K
- Patrick MeereNew York$191K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.